Mutation Clinical Trials in Chicago, Illinois
23 recruitingChicago, Illinois
Showing 1–20 of 23 trials
Recruiting
Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Not Applicable
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Breast CancerHead and Neck CancerGastrointestinal Cancer+2 more
University of Chicago860 enrolled1 locationNCT04541381
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
National Cancer Institute (NCI)28 enrolled22 locationsNCT05886049
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Not Applicable
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Ovarian CancerBRCA1 Gene MutationBRCA2 Gene Mutation+3 more
University Medical Center Nijmegen3,000 enrolled66 locationsNCT04294927
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1Phase 2
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier52 enrolled37 locationsNCT06501625
Recruiting
Phase 1
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.150 enrolled23 locationsNCT06366789
Recruiting
The Myelin Disorders Biorepository Project
AdrenoleukodystrophyCockayne SyndromeRefsum Disease+63 more
Children's Hospital of Philadelphia12,000 enrolled23 locationsNCT03047369
Recruiting
Phase 2
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
Northwestern University43 enrolled1 locationNCT05576896
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Recruiting
Phase 1
PRE-I-SPY Phase I/Ib Oncology Platform Program
Metastatic Breast CancerHER2-negative Breast CancerMetastatic Cancer+5 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting
Phase 2
Study of Olutasidenib and Temozolomide in HGG
Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974